Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.

Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol. 2010 Oct 10; 28(29):4500-6.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Alemtuzumab
Anemia
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Murine-Derived
Antibodies, Neoplasm
Antineoplastic Combined Chemotherapy Protocols
Disease-Free Survival
Drug Administration Schedule
Fatigue
Female
Humans
Injections, Subcutaneous
Leukemia, Lymphocytic, Chronic, B-Cell
Male
Middle Aged
Nausea
Neoplasm, Residual
Remission Induction
Rituximab
Treatment Outcome
Vidarabine
Young Adult

authors with profiles

Richard A. Larson